Navigation Links
Cord Blood America Revenues Up 37 Percent to $5.67 Million in 2011
Date:4/16/2012

LAS VEGAS, April 16, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that revenues for 2011 increased 37 percent to $5.67 million compared to $4.13 million in 2010.  The Company announced a gross profit increase in 2011 of $1.3 million, or 52 percent, to $3.8 million.

"We are pleased with the increase in revenues," said Matthew Schissler, co-founder and CEO.  "We are also pleased that we continue to reduce overhead and administrative expenses. Our efforts to reduce these expenses have paid and will continue to pay dividends for the Company and its investors."

The entire 10K is available at www.sec.gov

"Revenues were generated from our operations in the U.S., with our major storage facility in Las Vegas, and by our ownership or affiliations with companies in South America and Europe and revenue generation also occurred from placenta collection services for major tissue banks," Mr. Schissler said.

"The Company continues to report increases in revenue and gross profits.  While progress has been made on the expense side, we will continue to evaluate future actions that reduce both future costs and existing obligations.  We need to be very aggressive in this strategy," said Matthew Schissler, co-founder and CEO.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

 


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
2. Measuring blood flow to monitor sickle cell disease
3. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
5. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
6. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
7. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Study finds chronic abnormal brain blood flow in Gulf War veterans
11. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" ... that will be presented at the Company,s Annual and Special ... of Shareholders will take place on Thursday, December 15, 2016 ... Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, ... (MST). A notice of meeting and management information circular, containing ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced ... to the company,s Board of Directors. "We ... we build our business and develop our oncolytic viruses ... therapy," said Stephen Russell , MD, PhD, CEO ... , share our vision and passion for making a ...
(Date:12/7/2016)... , December 7, 2016 Regen BioPharma ... International Journal of Molecular Sciences a team of scientists in ... ] have demonstrated that expression of NR2F6 in patients ... tested for NR2F6 in patient,s cervical cancer tissue as well ... "This is an interesting study and the first ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... to an early access program for SmartBiome -- a novel metagenomic deep-sequencing ... simultaneous specific enrichment and detection of hundreds of different genes. The selective ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market by ... Area, End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, ... to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):